Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.

NCT02318667 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT02318667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02318667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 4
Overall status
Completed
Start date
February 27, 2015
Completion date
September 5, 2017
Enrollment
38 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative